does noom prescribe semaglutide Novo Nordisk expands Wegovy access as FDA bans copies Noom to offer GLP-1 drug

[DOI] [PubMed] [Google Scholar] Monopoli A., Calvano C

A study published in early 2025 found clear evidence that the share of prescriptions filled at PBM-owned pharmacies was substantially higher among patients enrolled in PBM-owned health plans, compared to patients covered by other insurers

According to the pharmaceutical industry on January 29, Roche announced the previous day the results of its Phase 2 clinical trial for CT-388, a dual agonist obesity treatment targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), and stated its intention to begin Phase 3 trials within the first quarter of this year

doi:10.3389/fphar.2025.1551843 Park JR, Lee H, Kim SI, Yang SR

Reading them in sequence makes the progression of incretin engineering legible in a way no review article captures

van den Wijngaard, R